Ex-Utero Intrapartum Treatment (EXIT): indications and outcome in fetal cervical and oropharyngeal masses.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
07 Oct 2020
Historique:
received: 28 04 2020
accepted: 30 09 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 18 5 2021
Statut: epublish

Résumé

The "Ex-Utero Intrapartum Treatment" (EXIT) procedure allows to ensure fetal airway before completion of delivery and umbilical cord clamping while keeping uteroplacental circulation. Airway obstruction in fetal oropharyngeal and cervical masses can be life-threatening at birth. In those situations, controlled access to fetal airway performed by a trained multidisciplinary team allows safe airway management, while feto-maternal circulation is preserved. We aim to review the indications and outcome of the EXIT procedure in a case series of fetal cervical and oropharyngeal masses. We have carried out a retrospective review of all patients with fetal cervical and oropharyngeal masses who underwent an EXIT procedure between 2008 and 2019. Variables evaluated included indication for EXIT, ultrasound and MRI findings, the need of amnioreduction, gestational age at EXIT, birth weight, complications, operative time, survival rate, pathological findings, and postnatal evolution. Five patients are included in this series. One additional case has already been published. The diagnosis were cervical teratoma (n = 1), epulis (n = 1) and lymphangioma (n = 3). Polyhydramnios was present in 2 patients, requiring amnioreduction in one of them. Mean gestational age at EXIT was 36-37 weeks (range, 34-38 weeks). Median EXIT time in placental support was 9 min (range, 3-22 min). Access to airway was successfully established in EXIT in all cases. All children born by EXIT are currently healthy and without complications. The localization and characteristics of the mass, its relationship to the airway, and the presence of polyhydramnios seem to be major factors determining indications for EXIT and clinical outcome.

Sections du résumé

BACKGROUND BACKGROUND
The "Ex-Utero Intrapartum Treatment" (EXIT) procedure allows to ensure fetal airway before completion of delivery and umbilical cord clamping while keeping uteroplacental circulation. Airway obstruction in fetal oropharyngeal and cervical masses can be life-threatening at birth. In those situations, controlled access to fetal airway performed by a trained multidisciplinary team allows safe airway management, while feto-maternal circulation is preserved. We aim to review the indications and outcome of the EXIT procedure in a case series of fetal cervical and oropharyngeal masses.
METHODS METHODS
We have carried out a retrospective review of all patients with fetal cervical and oropharyngeal masses who underwent an EXIT procedure between 2008 and 2019. Variables evaluated included indication for EXIT, ultrasound and MRI findings, the need of amnioreduction, gestational age at EXIT, birth weight, complications, operative time, survival rate, pathological findings, and postnatal evolution. Five patients are included in this series. One additional case has already been published.
RESULTS RESULTS
The diagnosis were cervical teratoma (n = 1), epulis (n = 1) and lymphangioma (n = 3). Polyhydramnios was present in 2 patients, requiring amnioreduction in one of them. Mean gestational age at EXIT was 36-37 weeks (range, 34-38 weeks). Median EXIT time in placental support was 9 min (range, 3-22 min). Access to airway was successfully established in EXIT in all cases. All children born by EXIT are currently healthy and without complications.
CONCLUSION CONCLUSIONS
The localization and characteristics of the mass, its relationship to the airway, and the presence of polyhydramnios seem to be major factors determining indications for EXIT and clinical outcome.

Identifiants

pubmed: 33028259
doi: 10.1186/s12884-020-03304-0
pii: 10.1186/s12884-020-03304-0
pmc: PMC7541246
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

598

Références

J Pediatr Surg. 2015 Feb;50(2):311-4
pubmed: 25638626
Semin Pediatr Surg. 2003 Aug;12(3):190-5
pubmed: 12961113
J Pediatr Surg. 1993 Apr;28(4):520-2
pubmed: 8483063
Anesth Analg. 1993 Jan;76(1):197-9
pubmed: 8418725
Semin Fetal Neonatal Med. 2010 Feb;15(1):34-9
pubmed: 19683972
Semin Neonatol. 2003 Jun;8(3):207-14
pubmed: 15001139
Radiographics. 2011 Mar-Apr;31(2):511-26
pubmed: 21415194
Ultrasound Obstet Gynecol. 2005 Jan;25(1):76-9; discussion 79
pubmed: 15619317
J Pediatr Surg. 2004 Mar;39(3):375-80; discussion 375-80
pubmed: 15017555
Semin Pediatr Surg. 2006 May;15(2):107-15
pubmed: 16616314
Biomed Imaging Interv J. 2008 Apr;4(2):e18
pubmed: 21614323
Can J Anaesth. 1994 Mar;41(3):236-40
pubmed: 8187259
J Pediatr Surg. 2012 Jan;47(1):46-50
pubmed: 22244391
Curr Opin Pediatr. 2012 Jun;24(3):386-93
pubmed: 22498672
Ann Otol Rhinol Laryngol. 1990 Mar;99(3 Pt 1):179-82
pubmed: 2310132
J Matern Fetal Neonatal Med. 2019 Mar;32(5):870-874
pubmed: 28992728
Obstet Gynecol. 1990 Nov;76(5 Pt 2):962-6
pubmed: 2216267
BMC Pregnancy Childbirth. 2014 Jul 30;14:252
pubmed: 25078677
J Pediatr Surg. 1996 Oct;31(10):1339-48
pubmed: 8906657
Prenat Diagn. 2001 Apr;21(4):308-10
pubmed: 11288123
J Pediatr Surg. 2020 Jul;55(7):1188-1195
pubmed: 32151401

Auteurs

Lutgardo García-Díaz (L)

Department of Materno-Fetal Medicine, Genetics, and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Avda. Manuel Siurot s/n ES-41013, Seville, Spain.

Angel Chimenea (A)

Department of Materno-Fetal Medicine, Genetics, and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Avda. Manuel Siurot s/n ES-41013, Seville, Spain.
Fetal, IVF and Reproduction Simulation Training Centre (FIRST), Seville, Spain.

Juan Carlos de Agustín (JC)

Department of Pediatric Surgery, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Antonio Pavón (A)

Department of Neonatology, Hospital Universitario Virgen del Rocio, Seville, Spain.

Guillermo Antiñolo (G)

Department of Materno-Fetal Medicine, Genetics, and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Avda. Manuel Siurot s/n ES-41013, Seville, Spain. gantinolo@us.es.
Fetal, IVF and Reproduction Simulation Training Centre (FIRST), Seville, Spain. gantinolo@us.es.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain. gantinolo@us.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH